Portfolio company
Clotprotect Therapeutics
United Kingdom
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
1 investor
Sectors
About
This company develops small molecule anti-fibrinolytic drugs for patients suffering from acute haemorrhage and severe bleeding.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
ClotProtect
This therapeutics company develops a small molecule drug to treat acute bleeding and improve survival for patients suffering from trauma or undergoing surgery.
Coagulant Therapeutics
This company develops medicines to treat acute bleeding conditions, such as postpartum haemorrhage and traumatic brain injury, for patients with urgent medical needs.
Cayuga Biotech
This company develops biomimetic injectable drugs to control life-threatening hemorrhage for patients suffering from trauma, childbirth complications or surgical bleeding.
VarmX
This biotech company develops recombinant blood clotting factors to treat patients with severe bleeding or requiring urgent surgery while taking oral anticoagulants.
RougeTx
This biotechnology company develops small-molecule therapies that restore vascular stability to treat patients with hereditary haemorrhagic telangiectasia and other bleeding disorders.
Alveron Pharma
Alveron Pharma develops a cyclodextrin-based injectable drug that reverses anticoagulant and antiplatelet effects for patients experiencing life-threatening bleeding emergencies and haemorrhagic strokes.
LUNAC Therapeutics
This drug discovery company develops next-generation anticoagulant therapies for patients requiring treatment for pathological blood clots with minimal bleeding risk.
ProteoValent Therapeutics
This company develops targeted protein degrader therapies for cancer and haematology patients.